FilingReader Intelligence

Maccura Biotechnology revenue falls 16%, profit down 83%

July 31, 2025 at 10:20 AM UTCBy FilingReader AI

Maccura Biotechnology reported a 15.94% revenue decrease for the first half of 2025, with net profit attributable to shareholders down 83.12%. The decline was influenced by divested agency operations and increased asset impairment charges.

The company will inject 1.6 billion yuan into two wholly-owned subsidiaries through debt-to-equity conversions to optimize capital structure.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:300463Shenzhen Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Maccura Biotechnology publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →